FASENRA (benralizumab) approved for eosinophilic granulomatosis with polyangiitis (EGPA)
This news item was issued on 8 April 2025 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.
ASCIA Members please log in to view.